Trial Profile
Sequential Phase II Study of the Anti-Idiotype Monoclonal Antibody Vaccine CeaVac and TriAb in Patients With Minimal Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2016
Price :
$35
*
At a glance
- Drugs Anti-idiotype cancer vaccine Titan Pharmaceuticals (Primary) ; Anti-idiotype cancer vaccine Titan Pharmaceuticals (Primary) ; Anti-idiotype CEA antibody vaccine (Primary) ; Anti-idiotype CEA antibody vaccine (Primary)
- Indications Cancer metastases; Colorectal cancer
- Focus Therapeutic Use
- 26 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 04 Apr 2011 Actual end date changed from Aug 2009 to Jun 2010 as reported by ClinicalTrials.gov.
- 01 Sep 2009 Actual end date (1 Aug 2009) added as reported by ClinicalTrials.gov.